Polynucleotides and exosomes are often mentioned in the same breath — as the "regenerative substances of the future." From safety, regulation, and evidence perspectives, however, the two stand at very different points. This article situates what is actually proven, what is approved, and which precautions follow from that — without symptom triage.
What both substances share — and where they differ
Both work regeneratively: they aim not at volume replacement but at stimulation of endogenous repair and regeneration processes. The similarity largely ends there.
Polynucleotides (PDRN, polydeoxyribonucleotides) are fragments derived from salmon DNA. They are CE-certified medical devices in several European countries and have been in clinical use for years. A review by Cavallini et al. (2021) in the Journal of Cosmetic Dermatology describes mechanism, safety, and clinical effects [1].
Exosomes are extracellular vesicles of cellular origin (e.g. from mesenchymal stem cells). They carry growth factors, miRNA, and other signalling molecules. Their regulatory situation is significantly more complex: in the EU, exosome products for aesthetic applications are not currently broadly approved. Applications often occur off-label or under individual medical responsibility.
Regulatory situation in Germany 2026
Polynucleotides: CE-certified medical devices with standardised manufacturing, batch control, and established protocols. In Germany part of the regular medical treatment spectrum.
Exosomes: The EU regulation on Advanced Therapy Medicinal Products (ATMP, EU 1394/2007) governs cell-based products strictly. Exosome preparations marketed as medicinal products with efficacy claims fall under this framework. Currently no exosome products are broadly approved for aesthetic indications in the EU.
A critical assessment by Phinney and Pittenger (2017) in Stem Cells describes the gap between promising preclinical data and the still-limited clinical evidence for exosome applications [2]. Translation: the concept is promising, clinical standardisation is incomplete.
More background on exosomes in our article on exosomes in aesthetics.
Evidence for polynucleotides
Polynucleotides have a broad clinical evidence base. A randomised controlled trial by Lee et al. (2020) in the Journal of Dermatological Treatment shows significant improvements in skin texture, hydration, and elasticity after three sessions [3]. Another review by Squadrito et al. (2017) describes anti-inflammatory and microcirculation-enhancing effects at the cellular level [4].
Safety profile: well documented. Local reactions (redness, swelling) for 24–48 hours. Severe complications are rare and described in the literature only as isolated cases — usually in the context of non-medical application or contaminated products. More in our article on polynucleotides for skin quality.
Evidence for exosomes
Preclinically (cell culture, animal models): extensive and promising. Clinically in humans: heterogeneous. A review by Sjoqvist et al. (2019) in Journal of Extracellular Vesicles emphasises the methodological diversity of published studies — different sources, preparations, dosages, complicating direct comparison [5].
Safety profile: the few well-controlled clinical studies show an overall favourable safety profile. However: the data base is significantly smaller than for polynucleotides, and product-to-product variability is high.
Where caution is warranted
The main problem is not the concept of exosomes but market reality. Three concrete risks:
1. Heterogeneous product quality
Exosome preparations vary widely in origin, processing, and characterisation. A product from stem cell cultures with standardised methods is not the same as one of unclear origin. Anyone using exosomes should be able to name the exact product and explain its regulatory status.
2. Off-label use and unclear advertising
Advertising with "stem cell treatment," "regenerative revolution," or similar buzzwords often violates § 3 HWG (misleading advertising). A serious practice clearly communicates that exosome applications do not currently have broad approvals for aesthetic indications.
3. Contamination and sterility
For products without CE certification as medical devices or without medicinal product approval, sterility standards are not regulatorily controlled. This risk is real — and from a patient perspective hard to verify.
When a practice uses which product
In my practice: polynucleotides are an established tool for skin quality, thin skin, eye area, regenerative indications. Exosomes I mention in consultation when patients ask — but I do not currently use them outside clinical trial protocols.
This restraint is not a rejection of the concept. It reflects regulatory and evidence reality. Once well-characterised products with clear approvals become available, this can change.
What patients should ask
With an offered exosome treatment, the following questions are sensible:
Which product exactly is used? Manufacturer, designation, regulatory status (CE medical device, medicinal product, individual preparation)?
Which clinical studies exist for this specific product?
How is sterility ensured?
Which informed consent regarding regulatory status is provided in writing?
Anyone receiving an evasive answer should decline the treatment and consider a practice that uses polynucleotides as an evidence-based alternative.
FAQ
Are exosomes inherently unsafe?
No — with standardised, well-characterised products in controlled clinical applications, the safety profile to date is favourable. The problem is market heterogeneity, not the concept.
Are polynucleotides legally approved?
Yes, as CE-certified medical devices in several European countries. Established, documented, with standardised application protocols.
How do I distinguish serious from non-serious advertising?
Serious providers name the exact product, its regulatory status, and the evidence base openly. Non-serious advertising works with buzzwords ("stem cell therapy," "regenerative revolution") without concrete product information.
Which substance has better evidence?
Polynucleotides — quantitatively and on clinical endpoints. Exosomes are very promising preclinically but heterogeneous clinically.
What will happen in coming years?
Regulatory clarification for exosome products is advancing. Once broadly approved, standardised preparations are available, clinical use will change. Currently: cautious, evidence-based application.
Should I wait for exosomes?
Anyone seeking regenerative skin improvement already has a well-supported tool with polynucleotides. Exosomes may complement them in future — currently they are not a replacement option with better evidence.
How likely are complications with polynucleotides?
With medical application, very rare. Local reactions are common, severe complications exceptional. More in our article on recognising complications.
Acute? Contact the treating practice immediately — no self-diagnosis. § 9 HWG (German Medicines Advertising Act) prohibits remote diagnosis. This article does not replace medical judgement.
References
- [1] Cavallini M, Bartoletti E, Maioli L, et al. Consensus report on the use of PN-HPT (Polynucleotides Highly Purified Technology) in aesthetic medicine. Journal of Cosmetic Dermatology. 2021;20(3):922-928. PubMed: 33522661
- [2] Phinney DG, Pittenger MF. Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. Stem Cells. 2017;35(4):851-858. PubMed: 28294454
- [3] Lee YJ, Kim HT, Lee WJ, et al. Effects of polynucleotide injection on skin elasticity and texture: a randomized controlled trial. Journal of Dermatological Treatment. 2020;31(8):860-867. PubMed: 31244347
- [4] Squadrito F, Bitto A, Irrera N, et al. Pharmacological activity and clinical use of PDRN. Frontiers in Pharmacology. 2017;8:224. PubMed: 28491036
- [5] Sjoqvist S, Ishikawa T, Shimura D, et al. Exosomes derived from clinical-grade oral mucosal epithelial cell sheets promote wound healing. Journal of Extracellular Vesicles. 2019;8(1):1565264. PubMed: 30719240
Last reviewed: May 2026. This article does not replace medical advice. Individual results may vary.
